OncoMatch/Clinical Trials/NCT07643012
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Is NCT07643012 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for endometrial cancer.
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institut Jersey · New Brunswick, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07643012 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages